Laura Brege
CIK: 0001365619
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Jun 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectDeferred Stock Units
2K shares- - Jun 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 10, 2026PCRX
Pacira BioSciences, Inc.
Award(A)Direct6.4K shares- - Jun 5, 2026EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
16.4K shares- - May 29, 2026ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectDirector Stock Options (Right to Buy)
16K shares- - May 29, 2026ACAD
ACADIA PHARMACEUTICALS INC
Exercise(M)Direct8.1K shares- - May 29, 2026ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Units
9.3K shares- - Sep 11, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct15.5K shares at avg. $74.34$1.2M - Sep 11, 2025MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct17K shares at avg. $15.00$255K - Sep 11, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1.5K shares at avg. $75.07$112K - Jun 16, 2025EWTX
Edgewise Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
30K shares- - Jun 11, 2025PCRX
Pacira BioSciences, Inc.
Award(A)Direct6.2K shares- - Jun 4, 2025ACAD
ACADIA PHARMACEUTICALS INC
Sale(S)Direct14.4K shares at avg. $21.78$315K - May 29, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
6.3K shares- - May 29, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectDeferred Stock Units
4K shares- - May 29, 2025MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct5.7K shares- - May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
Exercise(M)Direct9.4K shares- - May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectDirector Stock Options (Right to Buy)
13.8K shares- - May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Units
8.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 15, 2026 |  MIRM Mirum Pharmaceuticals, Inc. | Award(A) Deferred Stock Units | 1,980 | - | - | Direct |
| Jun 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,772 | - | - | Direct |
| Jun 10, 2026 |  PCRX Pacira BioSciences, Inc. | Award(A) | 6,405 | - | $0 | Direct |
| Jun 5, 2026 |  EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 16,377 | - | - | Direct |
| May 29, 2026 |  ACAD ACADIA PHARMACEUTICALS INC | Award(A) Director Stock Options (Right to Buy) | 16,004 | - | - | Direct |
| May 29, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Exercise(M) | 8,107 | - | $0 | Direct |
| May 29, 2026 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Restricted Stock Units | 9,311 | - | - | Direct |
| Sep 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 15,509 | $74.34 | $1,152,939 | Direct |
| Sep 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 17,000 | $15.00 | $255,000 | Direct |
| Sep 11, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,491 | $75.07 | $111,929 | Direct |
| Jun 16, 2025 | EWTX Edgewise Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 30,000 | - | - | Direct |
| Jun 11, 2025 | PCRX Pacira BioSciences, Inc. | Award(A) | 6,163 | - | - | Direct |
| Jun 4, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Sale(S) | 14,446 | $21.78 | $314,634 | Direct |
| May 29, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 6,268 | - | - | Direct |
| May 29, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Deferred Stock Units | 3,977 | - | - | Direct |
| May 29, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 5,703 | - | - | Direct |
| May 29, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Exercise(M) | 9,387 | - | - | Direct |
| May 29, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Director Stock Options (Right to Buy) | 13,793 | - | - | Direct |
| May 29, 2025 | ACAD ACADIA PHARMACEUTICALS INC | Award(A) Restricted Stock Units | 8,107 | - | - | Direct |
1-19 of 19 transactions
About Brege Laura
Brege Laura (SEC CIK 0001365619) files insider reports with the SEC as Director of Mirum Pharmaceuticals, Inc. (MIRM), Director of Edgewise Therapeutics, Inc. (EWTX) and Director of Pacira BioSciences, Inc. (PCRX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by Brege Laura, all Form 4s, filed between Jun 2, 2025 and Jun 17, 2026. Those filings report 19 transactions, from May 29, 2025 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Brege Laura's filings is in SAN DIEGO, CA.
Recent filings by Brege Laura
- Jun 15, 2026: Grants or awards of MIRM derivative securities (2 lines, Form 4, code A).
- Jun 10, 2026: Grant or award of PCRX shares (Form 4, code A).
- Jun 5, 2026: Grant or award of EWTX derivative securities (Form 4, code A).
- May 29, 2026: Grant or award of ACAD derivative securities (Form 4, code A).
- May 29, 2026: Option exercise of ACAD shares (Form 4, code M).
Other insiders filing for Mirum Pharmaceuticals, Inc. (MIRM)
- Howe Jolanda, SVP, GLOBAL CONTROLLER
- Myers Robert Paul, Chief Medical Officer
- Peetz Christopher, CHIEF EXECUTIVE OFFICER
- BJERKHOLT ERIC, CHIEF FINANCIAL OFFICER
- Walbert Timothy P, Director
- Cardon Lon, Director